Inviragen

This page shows the latest Inviragen news and features for those working in and with pharma, biotech and healthcare.

Sanofi's dengue vaccine could debut in 2015

Takeda is also developing a vaccine against dengue fever that was acquired along with other candidates when it took over Inviragen last year in a deal valued at up to $250m.

Latest news

Takeda buys vaccines specialist Inviragen

The biopharma company Inviragen, which has operations in the US and Singapore, will receive an upfront payment of $25m, and development and commercial milestones of up to $215m. ... In addition to its dengue vaccine, Takeda will also acquire the rights

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

Deal Watch table for May 2013

UAE based regional company $40m $244m option for 52%. 284. Inviragen/ Takeda.
Pharma deals during May 2013

targets from Abide; Takeda's $250m acquisition of Inviragen; GSK's $325m acquisition of the vaccine platform technology company, Okairos; and BMS's $112m licence for antibody conjugates from Ambrx. Note

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Medical Writer/ Senior Medical Writer opportunities – Macclesfie...: competitive salary and benefits package

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Women Leaders in UK Healthcare: Liz Henderson: Merck UK & Ireland’s MD on her ‘non-linear’ career and the importance of mentoring...
Webinar: Usability and UX: You’ve been asked to test...What next?: Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference: We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....